{"disease":{"id":"dasatinib","name":"dasatinib"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04155411","title":"Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CP","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":65,"lead_sponsor_name":"Shenzhen Second People's Hospital","has_results":false},{"nct_id":"NCT05523661","title":"Dasatinib Plus Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for Elderly Ph-positive ALL Patients","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":15,"lead_sponsor_name":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT04115059","title":"Dasatinib In Waldenström Macroglobulinemia","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"Jorge J. Castillo, MD","has_results":true}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}